Novo Nordisk

novonordisk.com

October 2026

Novo to present new liver data across Wegovy 2.4 mg and investigational efruxifermin at The Liver Meeting® (AASLD) 2026 email from Novo Nordisk

Novo to present new liver data across Wegovy 2.4 mg and investigational efruxifermin at The Liver Meeting® (AASLD) 2026

Captured October 28, 2026Announcement

Create this for my brand

Novo’s CagriSema was associated with 25% weight loss on average for women in a post hoc analysis of REDEFINE 1 presented at The Menopause Society Annual Meeting email from Novo Nordisk

Novo’s CagriSema was associated with 25% weight loss on average for women in a post hoc analysis of REDEFINE 1 presented at The Menopause Society Annual Meeting

Captured October 20, 2026Announcement

Create this for my brand

Novo provides update on the denecimig Biologics License Application (BLA) in the US email from Novo Nordisk

Novo provides update on the denecimig Biologics License Application (BLA) in the US

Captured October 2, 2026Announcement

Create this for my brand

Novo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat – EASD2026 email from Novo Nordisk

Novo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat – EASD2026

Captured October 1, 2026Announcement

Create this for my brand

September 2026

Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health – EASD 2026 email from Novo Nordisk

Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health – EASD 2026

Captured September 30, 2026Announcement

Create this for my brand

People switching from weight-loss injections to Novo's Wegovy® pill lost 4.1% body weight on average after three months, according to real-world data presented at EASD2026 email from Novo Nordisk

People switching from weight-loss injections to Novo's Wegovy® pill lost 4.1% body weight on average after three months, according to real-world data presented at EASD2026

Captured September 30, 2026Newsletter

Create this for my brand

Novo’s Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis email from Novo Nordisk

Novo’s Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis

Captured September 29, 2026Announcement

Create this for my brand

Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596 email from Novo Nordisk

Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596

Captured September 29, 2026Announcement

Create this for my brand

Novo and UNICEF expand partnership to support a healthier start for more than 80 million children email from Novo Nordisk

Novo and UNICEF expand partnership to support a healthier start for more than 80 million children

Captured September 22, 2026Announcement

Create this for my brand

Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial email from Novo Nordisk

Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial

Captured September 21, 2026Announcement

Create this for my brand

Highlights to be presented at Novo’s Capital Markets Day 2026 email from Novo Nordisk

Highlights to be presented at Novo’s Capital Markets Day 2026

Captured September 21, 2026Announcement

Create this for my brand

Novo’s once-weekly Sogroya® (somapacitan) receives positive CHMP opinion in Europe for children with idiopathic short stature (unexplained shortness) email from Novo Nordisk

Novo’s once-weekly Sogroya® (somapacitan) receives positive CHMP opinion in Europe for children with idiopathic short stature (unexplained shortness)

Captured September 18, 2026Announcement

Create this for my brand

Novo: CHMP recommends EU approval of FREHEMGO® (denecimig), the first factor VIIIa mimetic offering monthly, once every two weeks and weekly dosing in a pre-filled pen, for the treatment of haemophilia A email from Novo Nordisk

Novo: CHMP recommends EU approval of FREHEMGO® (denecimig), the first factor VIIIa mimetic offering monthly, once every two weeks and weekly dosing in a pre-filled pen, for the treatment of haemophilia A

Captured September 17, 2026Announcement

Create this for my brand

Novo’s denecimig demonstrates tolerability after switch from emicizumab in FRONTIER5 study of people with haemophilia A as published in the Journal of Thrombosis and Haemostasis email from Novo Nordisk

Novo’s denecimig demonstrates tolerability after switch from emicizumab in FRONTIER5 study of people with haemophilia A as published in the Journal of Thrombosis and Haemostasis

Captured September 17, 2026Newsletter

Create this for my brand

Novo and Anthropic will collaborate to advance drug discovery with Claude email from Novo Nordisk

Novo and Anthropic will collaborate to advance drug discovery with Claude

Captured September 16, 2026Announcement

Create this for my brand

Novo to share real-world and clinical data including Wegovy® pill, and cardiometabolic pipeline progress with next-generation amylin treatments at EASD 2026 email from Novo Nordisk

Novo to share real-world and clinical data including Wegovy® pill, and cardiometabolic pipeline progress with next-generation amylin treatments at EASD 2026

Captured September 16, 2026Announcement

Create this for my brand

Novo Nordisk enters next chapter to bring better health to more people, supported by ‘Novo’ rebrand and updated corporate culture email from Novo Nordisk

Novo Nordisk enters next chapter to bring better health to more people, supported by ‘Novo’ rebrand and updated corporate culture

Captured September 14, 2026Announcement

Create this for my brand

Novo Nordisk STEP Young phase 3 data: 40.4% of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modification email from Novo Nordisk

Novo Nordisk STEP Young phase 3 data: 40.4% of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modification

Captured September 7, 2026Announcement

Create this for my brand

August 2026

Novo Nordisk and AWS enter strategic partnership to accelerate drug discovery through AI email from Novo Nordisk

Novo Nordisk and AWS enter strategic partnership to accelerate drug discovery through AI

Captured August 10, 2026Announcement

Create this for my brand

Novo Nordisk wins Dutch court injunction protecting patients from unapproved, unlawful compounded semaglutide nasal spray email from Novo Nordisk

Novo Nordisk wins Dutch court injunction protecting patients from unapproved, unlawful compounded semaglutide nasal spray

Captured August 5, 2026Announcement

Create this for my brand

Novo Nordisk reports adjusted operating profit of DKK 33,389 million for Q2 2026 and raises full-year outlook email from Novo Nordisk

Novo Nordisk reports adjusted operating profit of DKK 33,389 million for Q2 2026 and raises full-year outlook

Captured August 4, 2026Announcement

Create this for my brand

Novo Nordisk raises adjusted sales and adjusted operating profit outlook for 2026 email from Novo Nordisk

Novo Nordisk raises adjusted sales and adjusted operating profit outlook for 2026

Captured August 4, 2026Announcement

Create this for my brand

July 2026

Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation email from Novo Nordisk

Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation

Captured July 31, 2026Announcement

Create this for my brand

Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli Lilly email from Novo Nordisk

Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli Lilly

Captured July 21, 2026Announcement

Create this for my brand

Explore styles used by Novo Nordisk